Exosome Diagnostics | Personalized Precision Healthcare

Skip to main content

• First and only molecular test to rule out high-grade prostate cancer • Completely non-invasive, non-DRE, urine-based liquid biopsy test • Easy-to-interpret results
The Power of RNA THE RIGHT THERAPY FOR THE RIGHT PATIENT AT THE RIGHT TIIME. The industry’s first exosome-based diagnostics are now available for clinicians.
Enabling more informed treatment decisions for non-small cell lung cancer.
Transforming patient care and improving lives Our tests provide comprehensive, real-time molecular insights as an aid to clinicians in disease detection, diagnosis, treatment, and monitoring.
A to D Program We can drive the regulatory pathway to commercialize your assay.

News & Events

RECENT NEWS

Tuesday, September 13, 2016

Exosome Diagnostics Appoints Elizabeth Cormier-May as Head of Commercial Diagnostics

Wednesday, September 7, 2016

Exosome Diagnostics Announces Launch of ExoDx^® Prostate(IntelliScore), a Completely Non-Invasive Liquid Biopsy Test to Help Rule Out High-Grade Prostate Cancer

Thursday, June 30, 2016

Exosome Diagnostics Enters Partnership with Takeda

UPCOMING EVENTS

August 21-26, 2016

Gordon Research Conference: Extracellular Vesicles

September 1-30, 2016

Prostate Cancer Awareness Month

September 16-18, 2016

First Global Summit on Precision Diagnosis for Prostate Cancer

View more News and Events

Order Tests

Now available to Heathcare Providers for Clinical Use: The Industry’s First Exosome-Based Liquid Biopsy Tests

Order Here

The Industry’s First RNA-Based Liquid Biopsies

We are bringing the first exosome-based diagnostics to market. Learn more about our Laboratory Developed Tests, which will be analyzed in our CLIA-certified laboratory:

Follow Us on Twitter

Tweets by @ExosomeDx

© Exosome Diagnostics 2016